Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Baxter
Colorcon

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pacritinib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Pacritinib: Sponsors, patents, clinical trial progress

Pacritinib is an investigational drug.

There have been 22 clinical trials for Pacritinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Thrombocythemia, Essential. The leading clinical trial sponsors are CTI BioPharma, Covance, and Washington University School of Medicine.

There are eleven US patents protecting this investigational drug and one hundred and seven international patents.

Recent Clinical Trials for Pacritinib
TitleSponsorPhase
Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersUniversity of Michigan Cancer CenterPhase 1
Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCovancePhase 2
Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCTI BioPharmaPhase 2

See all Pacritinib clinical trials

Clinical Trial Summary for Pacritinib

Top disease conditions for Pacritinib
Top clinical trial sponsors for Pacritinib

See all Pacritinib clinical trials

US Patents for Pacritinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pacritinib   See Pricing Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   See Pricing
Pacritinib   See Pricing Biomarkers and combination therapies using oncolytic virus and immunomodulation DNATRIX, INC. (Houston, TX) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   See Pricing
Pacritinib   See Pricing Oxygen linked pyrimidine derivatives S*BIO Pte Ltd. (Singapore, SG)   See Pricing
Pacritinib   See Pricing Oxygen linked pyrimidine derivatives Cell Therapeutics, Inc. (Seattle, WA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pacritinib

Drugname Country Document Number Estimated Expiration Related US Patent
Pacritinib Australia 2012345732 2031-11-30   See Pricing
Pacritinib Australia 2016244212 2031-11-30   See Pricing
Pacritinib Canada 2856722 2031-11-30   See Pricing
Pacritinib China 104185420 2031-11-30   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Colorcon
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.